The equilibrative nucleoside transporter family, SLC29

Pflugers Archiv European Journal of Physiology 447, 735-743 DOI: 10.1007/s00424-003-1103-2

Citation Report

#	Article	IF	CITATIONS
1	The Adenosine Transporter, mENT1, Is a Target for Adenosine Receptor Signaling and Protein Kinase Cϵ in Hypoxic and Pharmacological Preconditioning in the Mouse Cardiomyocyte Cell Line, HL-1. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 1190-1198.	1.3	35
2	Interconnections of CLN3, Hook1 and Rab proteins link Batten disease to defects in the endocytic pathway. Human Molecular Genetics, 2004, 13, 3017-3027.	1.4	122
3	TISSUE DISTRIBUTION OF CONCENTRATIVE AND EQUILIBRATIVE NUCLEOSIDE TRANSPORTERS IN MALE AND FEMALE RATS AND MICE. Drug Metabolism and Disposition, 2004, 32, 1455-1461.	1.7	117
4	Ecto-Nucleotidases and Nucleoside Transporters Mediate Activation of Adenosine Receptors on Hippocampal Mossy Fibers by P2X7 Receptor Agonist 2'-3'-O-(4-Benzoylbenzoyl)-ATP. Journal of Neuroscience, 2004, 24, 7128-7139.	1.7	74
5	Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia, 2004, 18, 385-393.	3.3	97
6	Nucleoside transporter subtype expression and function in rat skeletal muscle microvascular endothelial cells. British Journal of Pharmacology, 2004, 143, 202-214.	2.7	31
7	Electrophysiological characterization of a recombinant human Na+-coupled nucleoside transporter (hCNT1) produced inXenopusoocytes. Journal of Physiology, 2004, 558, 807-823.	1.3	84
8	Role of adenosine transport in gestational diabetes-inducedl-arginine transport and nitric oxide synthesis in human umbilical vein endothelium. Journal of Physiology, 2004, 560, 111-122.	1.3	87
9	Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption. European Journal of Pharmaceutical Sciences, 2004, 21, 3-16.	1.9	120
10	Detoxification systems, passive and specific transport for drugs at the blood?CSF barrier in normal and pathological situations. Advanced Drug Delivery Reviews, 2004, 56, 1717-1740.	6.6	87
11	Functional redundancy of two nucleoside transporters of the ENT family (CeENT1, CeENT2) required for development ofCaenorhabditis elegans. Molecular Membrane Biology, 2004, 21, 247-259.	2.0	10
12	Exploratory Chemoinformatic Analysis of Cell Type-Selective Anticancer Drug Targeting. Molecular Pharmaceutics, 2004, 1, 267-280.	2.3	3
13	Characterization of three novel members of the Arabidopsis thaliana equilibrative nucleoside transporter (ENT) family. Biochemical Journal, 2004, 383, 19-26.	1.7	69
14	Conditionally Immortalized Syncytiotrophoblast Cell Lines as New Tools for Study of the Blood-Placenta Barrier. Biological and Pharmaceutical Bulletin, 2004, 27, 753-759.	0.6	40
15	Tissue-specific mRNA Expression Profiles of Human ATP-binding Cassette and Solute Carrier Transporter Superfamilies. Drug Metabolism and Pharmacokinetics, 2005, 20, 452-477.	1.1	334
16	Inosine Infusion Prevents Mortality in Endotoxic Shock. Journal of Trauma, 2005, 59, 1432-1435.	2.3	10
17	The concentrative nucleoside transporter family (SLC28): new roles beyond salvage?. Biochemical Society Transactions, 2005, 33, 216-219.	1.6	19
18	Subtype-specific regulation of equilibrative nucleoside transporters by protein kinase CK2. Biochemical Journal, 2005, 386, 281-289.	1.7	25

#	Article	IF	CITATIONS
19	Functional characterization of adenosine transport across the BBB in mice. International Journal of Pharmaceutics, 2005, 290, 37-44.	2.6	16
20	Purine and pyrimidine transport in pathogenic protozoa: From biology to therapy. FEMS Microbiology Reviews, 2005, 29, 987-1020.	3.9	175
21	Adenosine A 2A receptors control the extracellular levels of adenosine through modulation of nucleoside transporters activity in the rat hippocampus. Journal of Neurochemistry, 2005, 93, 595-604.	2.1	79
22	Polarized distribution of nucleoside transporters in rat brain endothelial and choroid plexus epithelial cells. Journal of Neurochemistry, 2005, 94, 1420-1426.	2.1	77
23	Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia, 2005, 19, 64-68.	3.3	58
24	Expression systems for cloned xenobiotic transporters. Toxicology and Applied Pharmacology, 2005, 204, 256-262.	1.3	14
25	Equilibrative nucleoside transporter 2 is expressed in human umbilical vein endothelium, but is not involved in the inhibition of adenosine transport induced by hyperglycaemia. Placenta, 2005, 26, 641-653.	0.7	28
26	Growth regulation of the vascular system: an emerging role for adenosine. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2005, 289, R283-R296.	0.9	159
27	Functional Characterization of Novel Human and Mouse Equilibrative Nucleoside Transporters (hENT3 and mENT3) Located in Intracellular Membranes. Journal of Biological Chemistry, 2005, 280, 15880-15887.	1.6	271
28	AP-1 and AP-3 Facilitate Lysosomal Targeting of Batten Disease Protein CLN3 via Its Dileucine Motif. Journal of Biological Chemistry, 2005, 280, 10277-10283.	1.6	50
29	Control of Adenosine Transport by Hypoxia. Circulation Research, 2005, 97, 1-3.	2.0	56
30	Second-site Suppression of a Nonfunctional Mutation within the Leishmania donovani Inosine-Guanosine Transporter. Journal of Biological Chemistry, 2005, 280, 2213-2219.	1.6	30
31	Identification and Mutational Analysis of Amino Acid Residues Involved in Dipyridamole Interactions with Human and Caenorhabditis elegans Equilibrative Nucleoside Transporters. Journal of Biological Chemistry, 2005, 280, 11025-11034.	1.6	33
32	Role of Human Nucleoside Transporters in the Cellular Uptake of Two Inhibitors of IMP Dehydrogenase, Tiazofurin and Benzamide Riboside. Molecular Pharmacology, 2005, 67, 273-279.	1.0	17
33	Astrocytes and neurons: different roles in regulating adenosine levels. Neurological Research, 2005, 27, 153-160.	0.6	62
34	Purine Nucleosides Stimulate Na/K ATPase, and Prolong Survival in Hemorrhagic Shock. Journal of Trauma, 2005, 58, 1055-1060.	2.3	15
35	Equilibrative Nucleoside Transporter 1 Expression Is Downregulated by Hypoxia in Human Umbilical Vein Endothelium. Circulation Research, 2005, 97, 16-24.	2.0	77
36	HIF-1–dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. Journal of Experimental Medicine, 2005, 202, 1493-1505.	4.2	310

ARTICLE IF CITATIONS Interaction of Organic Cations with a Newly Identified Plasma Membrane Monoamine Transporter. 37 1.0 182 Molecular Pharmacology, 2005, 68, 1397-1407. Functional and pharmacological mechanisms of nucleoside transport across the basolateral membrane of rabbit tracheal epithelial cells. Life Sciences, 2005, 78, 310-320. 39 Cell entry and export of nucleoside analogues. Virus Research, 2005, 107, 151-164. 1.1 127 Uneven distribution of nucleoside transporters and intracellular enzymatic degradation prevent transport of intact [14C] adenosine across the sheep choroid plexus epithelium as a monolayer in 0.5 primary culture. Cerebrospinal Fluid Research, 2006, 3, 4. Renal nucleoside transporters: physiological and clinical implicationsThis paper is one of a selection of papers published in this Special Issue, entitled CSBMCB â€" Membrane Proteins in Health and Disease.. 41 0.9 48 Biochemistry and Cell Biology, 2006, 84, 844-858. Functional biology of the neuronal ceroid lipofuscinoses (NCL) proteins. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 920-933. 1.8 79 Functional and molecular characterization of adenosine transport at the rat inner blood–retinal 43 1.4 46 barrier. Biochimica Et Biophysica Acta - Biomembranes, 2006, 1758, 13-19. Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochemical and Biophysical Research 44 1.0 Communications, 2006, 343, 208-215. Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer 45 3.2 200 Letters, 2006, 239, 168-182. Localization of equilibrative nucleoside transporters in the rat brain. Journal of Chemical 1.0 Neuroanatomy, 2006, 31, 162-168. Nucleoside transporters: from scavengers to novel therapeutic targets. Trends in Pharmacological 47 4.0264 Sciences, 2006, 27, 416-425. Adenosine kinase, epilepsy and stroke: mechanisms and therapies. Trends in Pharmacological Sciences, 4.0 223 2006, 27, 652-658. Characterization of novel Na+-dependent nucleobase transport systems at the blood-testis barrier. 49 1.8 20 American Journal of Physiology - Endocrinology and Metabolism, 2006, 290, E968-E975. Cysteine-accessibility analysis of transmembrane domains 11–13 of human concentrative nucleoside 1.7 transporter 3. Biochemical Journal, 2006, 394, 389-398. Thirty Novel Genetic Variations in the SLC29A1 Gene Encoding Human Equilibrative Nucleoside 51 1.1 31 Transporter 1 (hENT1). Drug Metabolism and Pharmacokinetics, 2006, 21, 248-256. Identification of AtENT3 as the main transporter for uridine uptake in Arabidopsis roots. Cell Research, 2006, 16, 377-388. TGF-1² transcriptionally activates the gene encoding the high-affinity adenosine transporter CNT2 in rat 53 2.4 12 liver parenchymal cells. Cellular and Molecular Life Sciences, 2006, 63, 2527-2537. Molecular mechanisms underlying the enhanced sensitivity of thiopurine-resistant T-lymphoblastic 54 cell lines to methyl mercaptopurineriboside. Biochemical Pharmacology, 2006, 72, 816-823.

#	Article	IF	CITATIONS
55	Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5′-DFUR in breast cancer MCF7 cells. Biochemical Pharmacology, 2006, 72, 1646-1656.	2.0	27
56	The effect of acidosis on adenosine release from cultured rat forebrain neurons. Brain Research, 2006, 1082, 23-31.	1.1	5
57	Uridine and cytidine in the brain: Their transport and utilization. Brain Research Reviews, 2006, 52, 389-397.	9.1	145
58	Gestational diabetes and the adenosine/l-Arginine/nitric oxide (ALANO) pathway in human umbilical vein endothelium. Placenta, 2006, 27, 1-10.	0.7	98
59	Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. Journal of Cellular Physiology, 2006, 208, 451-460.	2.0	48
60	Insulin restores glucose inhibition of adenosine transport by increasing the expression and activity of the equilibrative nucleoside transporter 2 in human umbilical vein endothelium. Journal of Cellular Physiology, 2006, 209, 826-835.	2.0	44
61	Gene expression for enzymes and transporters involved in regulating adenosine and inosine levels in rat forebrain neurons, astrocytes and C6 glioma cells. Journal of Neuroscience Research, 2006, 84, 801-808.	1.3	40
62	Adenosine and Kidney Function. Physiological Reviews, 2006, 86, 901-940.	13.1	380
63	Ecto-5â€2-Nucleotidase (CD73)-Mediated Adenosine Production Is Tissue Protective in a Model of Bleomycin-Induced Lung Injury. Journal of Immunology, 2006, 176, 4449-4458.	0.4	118
64	FUNCTIONAL CHARACTERIZATION AND HAPLOTYPE ANALYSIS OF POLYMORPHISMS IN THE HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER, ENT2. Drug Metabolism and Disposition, 2006, 34, 12-15.	1.7	40
65	Distribution and Functional Characterization of Equilibrative Nucleoside Transporter-4, a Novel Cardiac Adenosine Transporter Activated at Acidic pH. Circulation Research, 2006, 99, 510-519.	2.0	181
66	Hypoxanthine Effect on Equilibrative and Concentrative Adenosine Transport in Human Lymphocytes. Implications in the Phatogenesis of Lesch-Nyhan Syndrome. Nucleosides, Nucleotides and Nucleic Acids, 2006, 25, 1065-1069.	0.4	3
67	Identification of the Mitochondrial Targeting Signal of the Human Equilibrative Nucleoside Transporter 1 (hENT1). Journal of Biological Chemistry, 2006, 281, 16700-16706.	1.6	95
68	Extracellular adenosine activates AMP-dependent protein kinase (AMPK). Journal of Cell Science, 2006, 119, 1612-1621.	1.2	87
69	Electrophysiological Characterization and Modeling of the Structure Activity Relationship of the Human Concentrative Nucleoside Transporter 3 (hCNT3). Molecular Pharmacology, 2006, 69, 1542-1553.	1.0	48
70	Residues 334 and 338 in Transmembrane Segment 8 of Human Equilibrative Nucleoside Transporter 1 Are Important Determinants of Inhibitor Sensitivity, Protein Folding, and Catalytic Turnover. Journal of Biological Chemistry, 2007, 282, 14148-14157.	1.6	40
71	Molecular Determinants of Substrate Selectivity of a Novel Organic Cation Transporter (PMAT) in the SLC29 Family. Journal of Biological Chemistry, 2007, 282, 3188-3195.	1.6	40
72	Conserved Glutamate Residues Are Critically Involved in Na+/Nucleoside Cotransport by Human Concentrative Nucleoside Transporter 1 (hCNT1). Journal of Biological Chemistry, 2007, 282, 30607-30617.	1.6	19

#	Article	IF	CITATIONS
73	Genomic analysis of nucleoside transporters in Diptera and functional characterization of DmENT2, a Drosophila equilibrative nucleoside transporter. Physiological Genomics, 2007, 28, 337-347.	1.0	11
74	Cardioprotective effects of novel tetrahydroisoquinoline analogs of nitrobenzylmercaptopurine riboside in an isolated perfused rat heart model of acute myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H2921-H2926.	1.5	6
75	Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells. American Journal of Physiology - Renal Physiology, 2007, 292, F682-F690.	1.3	73
76	Chemotherapeutic Strategies Against Trypanosoma brucei: Drug Targets vs. Drug Targeting. Current Pharmaceutical Design, 2007, 13, 555-567.	0.9	72
77	Regional Distribution of Solute Carrier mRNA Expression Along the Human Intestinal Tract. Drug Metabolism and Disposition, 2007, 35, 590-594.	1.7	205
78	Equilibrative Nucleoside (ENTs) and Cationic Amino Acid (CATs) Transporters: Implications in Foetal Endothelial Dysfunction in Human Pregnancy Diseases. Current Vascular Pharmacology, 2007, 5, 69-84.	0.8	51
79	Cell and Gene Therapies for Refractory Epilepsy. Current Neuropharmacology, 2007, 5, 115-125.	1.4	41
80	HYPERTONIC STRESS REGULATES T-CELL FUNCTION BY THE OPPOSING ACTIONS OF EXTRACELLULAR ADENOSINE TRIPHOSPHATE AND ADENOSINE. Shock, 2007, 27, 242-250.	1.0	27
81	Nucleoside transporter expression and adenosine uptake in the rat cochlea. NeuroReport, 2007, 18, 235-239.	0.6	8
82	Physiological Roles of Vascular Nucleoside Transporters. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1004-1013.	1.1	144
83	Transcription factors involved in the expression of SLC28 genes in human liver parenchymal cells. Biochemical and Biophysical Research Communications, 2007, 353, 381-388.	1.0	20
84	Synthesis, Flow Cytometric Evaluation, and Identification of Highly Potent Dipyridamole Analogues as Equilibrative Nucleoside Transporter 1 Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 3906-3920.	2.9	30
85	Nucleoside and nucleobase transporters of primary human cardiac microvascular endothelial cells: characterization of a novel nucleobase transporter. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H3325-H3332.	1.5	26
86	Characterization and Functional Analysis of the Promoter for the Human Equilibrative Nucleoside Transporter Gene, hENT1. Nucleosides, Nucleotides and Nucleic Acids, 2007, 26, 99-110.	0.4	17
87	Differential regulation of mouse equilibrative nucleoside transporter 1 (mENT1) splice variants by protein kinase CK2. Molecular Membrane Biology, 2007, 24, 294-303.	2.0	24
88	Nucleoside Transport Into Cells. , 2006, , 1-28.		3
89	The Biology and Function of Transporters. , 2007, , 51-85.		7
90	Novel C2-purine position analogs of nitrobenzylmercaptopurine riboside as human equilibrative nucleoside transporter 1 inhibitors. Bioorganic and Medicinal Chemistry, 2007, 15, 7726-7737.	1.4	10

#	Article	IF	Citations
91	Nucleoside transporter expression and activity is regulated during granulocytic differentiation of NB4 cells in response to all-trans-retinoic acid. Leukemia Research, 2007, 31, 955-968.	0.4	4
92	Role of CNT3 in the transepithelial flux of nucleosides and nucleoside-derived drugs. Journal of Physiology, 2007, 582, 1249-1260.	1.3	57
93	Control of basal extracellular adenosine concentration in rat cerebellum. Journal of Physiology, 2007, 582, 137-151.	1.3	60
94	Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs. European Journal of Neuroscience, 2007, 26, 3237-3252.	1.2	65
95	Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides. Cancer Science, 2007, 98, 1633-1637.	1.7	36
96	The type 1 equilibrative nucleoside transporter regulates anxiety-like behavior in mice. Genes, Brain and Behavior, 2007, 6, 776-783.	1.1	61
97	Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochimica Et Biophysica Acta: Reviews on Cancer, 2007, 1776, 138-159.	3.3	46
98	Inhibition of human equilibrative nucleoside transporters by dihydropyridine-type calcium channel antagonists. European Journal of Pharmacology, 2007, 568, 75-82.	1.7	19
99	Adenosine dysfunction in astrogliosis: cause for seizure generation?. Neuron Glia Biology, 2007, 3, 353-366.	2.0	108
100	The Origin of Deoxynucleosides in Brain: Implications for the Study of Neurogenesis and Stem Cell Therapy. Pharmaceutical Research, 2007, 24, 859-867.	1.7	21
101	The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer and Metastasis Reviews, 2007, 26, 85-110.	2.7	202
102	Characterization of the Mechanism of Zidovudine Uptake by Rat Conditionally Immortalized Syncytiotrophoblast Cell Line TR-TBT. Pharmaceutical Research, 2008, 25, 1647-1653.	1.7	22
103	Effect of chronic gestational treatment with the adenosine A ₁ receptor agonist Râ€phenylisopropyladenosine on metabotropic glutamate receptors/phospholipase C pathway in maternal and fetal brain. Journal of Neuroscience Research, 2008, 86, 3295-3305.	1.3	5
104	Renal excretion of emtricitabine I: Effects of organic anion, organic cation, and nucleoside transport inhibitors on emtricitabine excretion. Journal of Pharmaceutical Sciences, 2008, 97, 5401-5410.	1.6	16
105	High <scp>D</scp> â€glucose reduces <i>SLC29A1</i> promoter activity and adenosine transport involving specific protein 1 in human umbilical vein endothelium. Journal of Cellular Physiology, 2008, 215, 645-656.	2.0	27
106	Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H. Leukemia Research, 2008, 32, 1268-1278.	0.4	19
107	Kinetics of nucleoside uptake by the basolateral side of the sheep choroid plexus epithelium perfused <i>in situ</i> . Experimental Physiology, 2008, 93, 325-333.	0.9	5
108	Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2′-deoxycytidine analog. Nature Medicine, 2008, 14, 783-788.	15.2	185

#	Article	IF	CITATIONS
109	Novel interactions of CLN3 protein link Batten disease to dysregulation of fodrin–Na+, K+ ATPase complex. Experimental Cell Research, 2008, 314, 2895-2905.	1.2	45
110	The transmembrane topology of Batten disease protein CLN3 determined by consensus computational prediction constrained by experimental data. FEBS Letters, 2008, 582, 1019-1024.	1.3	38
111	Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells. Biochemical Pharmacology, 2008, 75, 639-648.	2.0	23
112	Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia. Biochemical Pharmacology, 2008, 75, 857-865.	2.0	18
113	Cytotoxic activities of nucleoside and nucleobase analog drugs in malignant mesothelioma: Characterization of a novel nucleobase transport activity. Biochemical Pharmacology, 2008, 75, 1901-1911.	2.0	8
114	Contribution of Na+-independent nucleoside transport to ribavirin uptake in the rat intestine and human epithelial LS180 cells. European Journal of Pharmacology, 2008, 601, 61-65.	1.7	13
115	Kinetic and mutational analysis of the Trypanosoma brucei NBT1 nucleobase transporter expressed in Saccharomyces cerevisiae reveals structural similarities between ENT and MFS transporters. International Journal for Parasitology, 2008, 38, 641-653.	1.3	18
116	Regulation of enteric functions by adenosine: Pathophysiological and pharmacological implications. , 2008, 120, 233-253.		103
117	A Hypothesis for Preeclampsia: Adenosine and Inducible Nitric Oxide Synthase in Human Placental Microvascular Endothelium. Placenta, 2008, 29, 469-483.	0.7	59
118	Human Equilibrative Nucleoside Transporters 1 and 2 may be Differentially Modulated by A2B Adenosine Receptors in Placenta Microvascular Endothelial Cells from Pre-eclampsia. Placenta, 2008, 29, 816-825.	0.7	60
119	Basal Expression of Nucleoside Transporter mRNA Differs Among Small Intestinal Epithelia of Beef Steers and Is Differentially Altered by Ruminal or Abomasal Infusion of Starch Hydrolysate. Journal of Dairy Science, 2008, 91, 1570-1584.	1.4	15
120	Physiological and Pharmacological Roles of Nucleoside Transporter Proteins. Nucleosides, Nucleotides and Nucleic Acids, 2008, 27, 769-778.	0.4	40
121	Hypoxanthine uptake and release by equilibrative nucleoside transporter 2 (ENT2) of rat microvascular endothelial cells. Microvascular Research, 2008, 75, 351-357.	1.1	17
122	ATP and acetylcholine, equal brethren. Neurochemistry International, 2008, 52, 634-648.	1.9	70
123	Transport of [14C]hypoxanthine by sheep choroid plexus epithelium as a monolayer in primary culture: Na+-dependent and Na+-independent uptake by the apical membrane and rapid intracellular metabolic conversion to nucleotides. Neuroscience Letters, 2008, 431, 135-140.	1.0	6
124	The adenosine kinase hypothesis of epileptogenesis. Progress in Neurobiology, 2008, 84, 249-262.	2.8	210
125	Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica, 2008, 38, 995-1021.	0.5	181
126	Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses. Alzheimer's and Dementia, 2008, 4, S153-68.	0.4	77

#	Article	IF	CITATIONS
127	Synthesis and in Vitro Evaluation of 5-[18F]Fluoroalkyl Pyrimidine Nucleosides for Molecular Imaging of Herpes Simplex Virus Type 1 Thymidine Kinase Reporter Gene Expression. Journal of Medicinal Chemistry, 2008, 51, 5690-5701.	2.9	8
128	Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue. Journal of Clinical Oncology, 2008, 26, 4966-4972.	0.8	101
129	Monitoring in Vivo Metabolism and Elimination of the Endogenous DNA Adduct, M1dG {3-(2-Deoxy-β-d-erythro-pentofuranosyl)pyrimido[1,2-α]purin-10(3H)-one}, by Accelerator Mass Spectrometryâ€. Chemical Research in Toxicology, 2008, 21, 1290-1294.	1.7	20
130	High expression of nucleoside transporter protein hENT1 in Reed–Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin – A CALGB 59804 correlative study. Leukemia and Lymphoma, 2008. 49. 1202-1205.	0.6	10
131	A Conformationally Mobile Cysteine Residue (Cys-561) Modulates Na+ and H+ Activation of Human CNT3. Journal of Biological Chemistry, 2008, 283, 24922-24934.	1.6	17
132	IntestinalTransporters in Drug Absorption. , 2008, , 175-261.		5
133	Administration of Docosahexaenoic Acid, Uridine and Choline Increases Levels of Synaptic Membranes and Dendritic Spines in Rodent Brain. World Review of Nutrition and Dietetics, 2008, 99, 71-96.	0.1	19
134	Characterization of mENT1î"11, a Novel Alternative Splice Variant of the Mouse Equilibrative Nucleoside Transporter 1. Molecular Pharmacology, 2008, 74, 264-273.	1.0	10
135	Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells. Haematologica, 2008, 93, 1843-1851.	1.7	20
136	In Vivo Evaluation of the Uptake of [123I]FIAU, [123I]IVFRU and [123I]IVFAU by Normal Mouse Brain: Potential For Noninvasive Assessment of HSV-1 Thymidine Kinase Gene Expression in Gliomas. Nucleosides, Nucleotides and Nucleic Acids, 2008, 27, 57-66.	0.4	3
137	Expression and Functionality of Anti-Human Immunodeficiency Virus and Anticancer Drug Uptake Transporters in Immune Cells. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 558-567.	1.3	66
138	Inosine and equilibrative nucleoside transporter 2 contribute to hypoxic preconditioning in the murine cardiomyocyte HL-1 cell line. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H2687-H2692.	1.5	13
139	Organic Anion Transporter 2 (<i>SLC22A7</i>) Is a Facilitative Transporter of cGMP. Molecular Pharmacology, 2008, 73, 1151-1158.	1.0	103
140	Purine and Pyrimidine Metabolism in Leishmania. Advances in Experimental Medicine and Biology, 2008, 625, 141-154.	0.8	78
141	A Proton-mediated Conformational Shift Identifies a Mobile Pore-lining Cysteine Residue (Cys-561) in Human Concentrative Nucleoside Transporter 3. Journal of Biological Chemistry, 2008, 283, 8496-8507.	1.6	16
142	Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes. American Journal of Physiology - Renal Physiology, 2008, 295, G570-G580.	1.6	61
143	Physiology of Nucleoside Transporters: Back to the Future Physiology, 2008, 23, 41-48.	1.6	40
144	Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). International Journal of Oncology, 0, , .	1.4	97

	CITATION		
#	Article	IF	CITATIONS
145	Astrogliosis and adenosine kinase: a glial basis of epilepsy. Future Neurology, 2008, 3, 221-224.	0.9	9
146	Adenosine Transporter ENT4 Is a Direct Target of EWS/WT1 Translocation Product and Is Highly Expressed in Desmoplastic Small Round Cell Tumor. PLoS ONE, 2008, 3, e2353.	1.1	47
147	SLC29A3 gene is mutated in pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome and interacts with the insulin signaling pathway. Human Molecular Genetics, 2009, 18, 2257-2265.	1.4	100
148	Effects of omeprazole treatment on nucleoside transporter expression and adenosine uptake in rat gastric mucosa. Canadian Journal of Physiology and Pharmacology, 2009, 87, 402-410.	0.7	4
149	Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation. Molecular Cancer Therapeutics, 2009, 8, 225-231.	1.9	56
150	Nucleoside/nucleobase transporters: drug targets of the future?. Future Medicinal Chemistry, 2009, 1, 303-326.	1.1	17
151	Inhibition of the Equilibrative Nucleoside Transporter 1 and Activation of A2A Adenosine Receptors by 8-(4-Chlorophenylthio)-modified cAMP Analogs and Their Hydrolytic Products. Journal of Biological Chemistry, 2009, 284, 32256-32263.	1.6	11
152	Conserved Glutamate Residues Glu-343 and Glu-519 Provide Mechanistic Insights into Cation/Nucleoside Cotransport by Human Concentrative Nucleoside Transporter hCNT3. Journal of Biological Chemistry, 2009, 284, 17266-17280.	1.6	15
153	Substituted Cysteine Accessibility Method Analysis of Human Concentrative Nucleoside Transporter hCNT3 Reveals a Novel Discontinuous Region of Functional Importance within the CNT Family Motif (G/A)XKX3NEFVA(Y/M/F). Journal of Biological Chemistry, 2009, 284, 17281-17292.	1.6	13
154	A splice variant of the <i>SLC28A3</i> gene encodes a novel human concentrative nucleoside transporterâ€3 (hCNT3) protein localized in the endoplasmic reticulum. FASEB Journal, 2009, 23, 172-182.	0.2	42
155	Decreased Nucleoside Transport and hENT1 Transporter Expression in Beta-Thalassemia Major. Medical Principles and Practice, 2009, 18, 180-186.	1.1	3
156	Giving Uridine and/or Docosahexaenoic Acid Orally to Rat Dams during Gestation and Nursing Increases Synaptic Elements in Brains of Weanling Pups. Developmental Neuroscience, 2009, 31, 181-192.	1.0	35
157	Adenosine and the Auditory System. Current Neuropharmacology, 2009, 7, 246-256.	1.4	46
158	Transepithelial fluxes of adenosine and 2′-deoxyadenosine across human renal proximal tubule cells: roles of nucleoside transporters hENT1, hENT2, and hCNT3. American Journal of Physiology - Renal Physiology, 2009, 296, F1439-F1451.	1.3	27
159	Human Nucleoside Transporters: Biomarkers for Response to Nucleoside Drugs. Nucleosides, Nucleotides and Nucleic Acids, 2009, 28, 450-463.	0.4	29
160	Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. American Journal of Physiology - Renal Physiology, 2009, 296, G910-G922.	1.6	120
161	Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance. Journal of Virology, 2009, 83, 4538-4547.	1.5	57
162	<i>S. pombe btn1</i> , the orthologue of the Batten disease gene <i>CLN3</i> , is required for vacuole protein sorting of Cpy1p and Golgi exit of Vps10p. Journal of Cell Science, 2009, 122, 1163-1173.	1.2	43

#	Article	IF	CITATIONS
163	Adenosine signaling and the regulation of chronic lung disease. , 2009, 123, 105-116.		102
164	Altered gene transcription profiles in fibroblasts harboring either TK2 or DGUOK mutations indicate compensatory mechanisms. Experimental Cell Research, 2009, 315, 1429-1438.	1.2	9
165	The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further research. Antiviral Research, 2009, 82, A99-A109.	1.9	182
166	Identification of a novel point mutation in ENT1 that confers resistance to Ara in human T cell leukemia CCRFâ€CEM cells. FEBS Letters, 2009, 583, 425-429.	1.3	22
167	Inhibitory effect of nonsteroidal anti-inflammatory drugs on adenosine transport in vascular smooth muscle cells. European Journal of Pharmacology, 2009, 612, 15-20.	1.7	10
168	Mechanisms of induction of adenosine receptor genes and its functional significance. Journal of Cellular Physiology, 2009, 218, 35-44.	2.0	72
169	Blood–Brain Barrier Efflux Transport of Pyrimidine Nucleosides and Nucleobases in the Rat. Neurochemical Research, 2009, 34, 566-573.	1.6	10
170	Inner Blood-Retinal Barrier Transporters: Role of Retinal Drug Delivery. Pharmaceutical Research, 2009, 26, 2055-2065.	1.7	89
171	Synapse formation is enhanced by oral administration of uridine and DHA, the circulating precursors of brain phosphatides. Journal of Nutrition, Health and Aging, 2009, 13, 189-197.	1.5	70
172	Human concentrative nucleoside transporter 3 is a determinant of fludarabine transportability and cytotoxicity in human renal proximal tubule cell cultures. Cancer Chemotherapy and Pharmacology, 2009, 63, 289-301.	1.1	13
173	Adenosine signalling at immature parallel fibre–Purkinje cell synapses in rat cerebellum. Journal of Physiology, 2009, 587, 4497-4508.	1.3	13
174	Ethanol Blocks Adenosine Uptake via Inhibiting the Nucleoside Transport System in Bronchial Epithelial Cells. Alcoholism: Clinical and Experimental Research, 2009, 33, 791-798.	1.4	26
175	Transgenic expression of human equilibrative nucleoside transporter 1 in mouse neurons. Journal of Neurochemistry, 2009, 109, 562-572.	2.1	30
176	Adenosine augmentation therapies (AATs) for epilepsy: Prospect of cell and gene therapies. Epilepsy Research, 2009, 85, 131-141.	0.8	73
177	CoMFA and CoMSIA 3D-QSAR studies on S6-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1). Bioorganic and Medicinal Chemistry Letters, 2009, 19, 314-318.	1.0	11
178	Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 917-921.	1.0	28
179	Disrupted plasma membrane localization and loss of function reveal regions of human equilibrative nucleoside transporter 1 involved in structural integrity and activity. Biochimica Et Biophysica Acta - Biomembranes, 2009, 1788, 2326-2334.	1.4	10
180	Cloning and pharmacological characterization of a novel gene encoding human nucleoside transporter 1 (hNT1) from a human breast cancer cDNA library. Life Sciences, 2009, 84, 45-51.	2.0	4

#	ARTICLE	IF	CITATIONS
181	Adenosine Receptors and Inflammation. Handbook of Experimental Pharmacology, 2009, , 215-269.	0.9	136
182	Drug Distribution. , 2009, , 113-129.		3
183	TGF-β1 inhibits expression and activity of hENT1 in a nitric oxide-dependent manner in human umbilical vein endothelium. Cardiovascular Research, 2009, 82, 458-467.	1.8	20
184	Characterization of Nucleobase Transport by Mouse Sertoli Cell Line TM4. Biological and Pharmaceutical Bulletin, 2009, 32, 450-455.	0.6	12
185	Membrane Transport Mechanisms of Mizoribine in the Rat Intestine and Human Epithelial LS180 Cells. Biological and Pharmaceutical Bulletin, 2009, 32, 741-745.	0.6	15
186	Equilibrative Nucleoside Transporters in Fetal Endothelial Dysfunction in Diabetes Mellitus and Hyperglycaemia. Current Vascular Pharmacology, 2009, 7, 435-449.	0.8	31
187	Transport Characteristics of Ribavirin in Human Erythrocyte Membrane Vesicles. Membrane, 2010, 35, 297-304.	0.0	0
188	A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Molecular Membrane Biology, 2010, 27, 260-273.	2.0	74
189	Effects of Hypoxia, Glucose Deprivation and Recovery on the Expression of Nucleoside Transporters and Adenosine Uptake in Primary Culture of Rat Cortical Astrocytes. Neurochemical Research, 2010, 35, 1434-1444.	1.6	12
190	Vectorial Ligand Transport Through Mammalian Choroid Plexus. Pharmaceutical Research, 2010, 27, 2054-2062.	1.7	35
191	Differential expression of functional nucleoside transporters in non-differentiated and differentiated human endothelial progenitor cells. Placenta, 2010, 31, 928-936.	0.7	15
192	Nucleoside transporter expression profiles in human cardiac tissue show striking individual variability with overall predominance of hENT1. European Journal of Pharmaceutical Sciences, 2010, 41, 685-691.	1.9	6
193	Interaction of benzopyranone derivatives and related compounds with human concentrative nucleoside transporters 1, 2 and 3 heterologously expressed in porcine PK15 nucleoside transporter deficient cells. Structure–activity relationships and determinants of transporter affinity and selectivity. Biochemical Pharmacology, 2010, 79, 307-320.	2.0	22
194	Thiopurines: Factors influencing toxicity and response. Biochemical Pharmacology, 2010, 79, 1211-1220.	2.0	52
195	Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma. Hepatology, 2010, 52, 1690-1701.	3.6	60
196	The accumulation and metabolism of zidovudine in 3T3â€F442A preâ€adipocytes. British Journal of Pharmacology, 2010, 159, 484-493.	2.7	8
197	Adenosine signaling and function in glial cells. Cell Death and Differentiation, 2010, 17, 1071-1082.	5.0	259
198	Ecto-5′-Nucleotidase and Thiopurine Cellular Circulation: Association with Cytotoxicity. Drug Metabolism and Disposition, 2010, 38, 2329-2338.	1.7	16

#	Article	IF	CITATIONS
199	Identification and Functional Characterization of the First Nucleobase Transporter in Mammals. Journal of Biological Chemistry, 2010, 285, 6522-6531.	1.6	75
200	Nitric oxide reduces SLC29A1 promoter activity and adenosine transport involving transcription factor complex hCHOP–C/EBPα in human umbilical vein endothelial cells from gestational diabetes. Cardiovascular Research, 2010, 86, 45-54.	1.8	49
201	All-trans-retinoic Acid Promotes Trafficking of Human Concentrative Nucleoside Transporter-3 (hCNT3) to the Plasma Membrane by a TGF-β1-mediated Mechanism. Journal of Biological Chemistry, 2010, 285, 13589-13598.	1.6	21
202	Transmembrane Segment 11 Appears to Line the Purine Permeation Pathway of the Plasmodium falciparum Equilibrative Nucleoside Transporter 1 (PfENT1). Journal of Biological Chemistry, 2010, 285, 17001-17010.	1.6	23
203	Manipulation of Adenosine Kinase Affects Sleep Regulation in Mice. Journal of Neuroscience, 2010, 30, 13157-13165.	1.7	68
204	Human Equilibrative Nucleoside Transporter-3 (hENT3) Spectrum Disorder Mutations Impair Nucleoside Transport, Protein Localization, and Stability. Journal of Biological Chemistry, 2010, 285, 28343-28352.	1.6	76
205	Testicular Expression of Adora3i2 in Adora3 Knockout Mice Reveals a Role of Mouse A3Ri2 and Human A3Ri3 Adenosine Receptors in Sperm*. Journal of Biological Chemistry, 2010, 285, 33662-33670.	1.6	24
206	Nucleoside/nucleobase transport and metabolism by microvascular endothelial cells isolated from ENT1 ^{â^²/â²²} mice. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H847-H856.	1.5	20
207	Role of Nucleoside Transporters in Nucleoside-Derived Drug Sensitivity. Nucleosides, Nucleotides and Nucleic Acids, 2010, 29, 335-346.	0.4	10
208	Human Erythrocyte Nucleoside Transporter ENT1 Functions at Ice-cold Temperatures. Drug Metabolism and Pharmacokinetics, 2010, 25, 351-360.	1.1	16
209	Adenosine Transport by Plasma Membrane Monoamine Transporter: Reinvestigation and Comparison with Organic Cations. Drug Metabolism and Disposition, 2010, 38, 1798-1805.	1.7	36
210	Tyrosine 112 Is Essential for Organic Cation Transport by the Plasma Membrane Monoamine Transporter. Biochemistry, 2010, 49, 7839-7846.	1.2	11
211	Adenosine Release Evoked by Short Electrical Stimulations in Striatal Brain Slices Is Primarily Activity Dependent. ACS Chemical Neuroscience, 2010, 1, 775-787.	1.7	48
212	The role of blood–ocular barrier transporters in retinal drug disposition: an overview. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1111-1124.	1.5	67
213	Adaptive responses to purine starvation in <i>Leishmania donovani</i> . Molecular Microbiology, 2010, 78, 92-107.	1.2	49
214	Methylxanthines, Seizures, and Excitotoxicity. Handbook of Experimental Pharmacology, 2011, , 251-266.	0.9	66
216	The Cell. , 2011, , 1-43.		1
217	Les nucléosides et nucléotides extracellulaires régulent les fonctions hépatiques par le biais d'un système complexe de protéines membranaires. Comptes Rendus - Biologies, 2011, 334, 100-117.	0.1	20

#	Article	IF	CITATIONS
218	Molecular mechanisms of nucleoside recycling in the brain. International Journal of Biochemistry and Cell Biology, 2011, 43, 140-145.	1.2	19
219	Regulation of ENT1 expression and ENT1-dependent nucleoside transport by c-Jun N-terminal kinase. Biochemical and Biophysical Research Communications, 2011, 404, 370-375.	1.0	21
220	Organic anion and cation transporters are possibly involved in renal excretion of entecavir in rats. Life Sciences, 2011, 89, 1-6.	2.0	19
221	Targeted endoradiotherapy using nucleotides. Methods, 2011, 55, 203-214.	1.9	12
222	Membrane transport of sepiapterin and dihydrobiopterin by equilibrative nucleoside transporters: A plausible gateway for the salvage pathway of Tetrahydrobiopterin biosynthesis. Molecular Genetics and Metabolism, 2011, 102, 18-28.	0.5	26
223	Opposite modulation of astroglial proliferation by adenosine 5′-O-(2-thio)-diphosphate and 2-methylthioadenosine-5′-diphosphate: mechanisms involved. Neuroscience, 2011, 182, 32-42.	1.1	21
224	Long evolutionary conservation and considerable tissue specificity of several atypical solute carrier transporters. Gene, 2011, 478, 11-18.	1.0	50
225	Editorial NeuroAIDS review. Aids, 2011, 25, 123-141.	1.0	90
226	Modulators of Nucleoside Metabolism in the Therapy of Brain Diseases. Current Topics in Medicinal Chemistry, 2011, 11, 1068-1086.	1.0	47
227	Cell-specific Synergic Effect of Cimicifugoside on Cytotoxicity of Methotrexate. Journal of Health Science, 2011, 57, 350-355.	0.9	0
229	Immune cell regulation by autocrine purinergic signalling. Nature Reviews Immunology, 2011, 11, 201-212.	10.6	680
230	Review: Differential placental macrovascular and microvascular endothelial dysfunction in gestational diabetes. Placenta, 2011, 32, S159-S164.	0.7	100
231	The life cycle of human equilibrative nucleoside transporter 1: From ER export to degradation. Experimental Cell Research, 2011, 317, 1567-1579.	1.2	19
232	Interaction of fused-pyrimidine nucleoside analogs with human concentrative nucleoside transporters: High-affinity inhibitors of human concentrative nucleoside transporter 1. Biochemical Pharmacology, 2011, 81, 82-90.	2.0	21
233	Adenosine and blood platelets. Purinergic Signalling, 2011, 7, 357-365.	1.1	78
234	Population pharmacokinetics of mizoribine in adult recipients of renal transplantation. Clinical and Experimental Nephrology, 2011, 15, 900-906.	0.7	13
235	Glial solute carrier transporters in <i>drosophila</i> and mice. Glia, 2011, 59, 1351-1363.	2.5	44
236	Influence of Sugar Ring Conformation on the Transportability of Nucleosides by Human Nucleoside Transporters. ChemBioChem, 2011, 12, 2774-2778.	1.3	13

			2
#	ARTICLE Insulin Restores Gestational Diabetes Mellitus–Reduced Adenosine Transport Involving Differential	IF	CITATIONS
237	Expression of Insulin Receptor Isoforms in Human Umbilical Vein Endothelium. Diabetes, 2011, 60, 1677-1687.	0.3	101
238	Intracellular ATP Influences Synaptic Plasticity in Area CA1 of Rat Hippocampus via Metabolism to Adenosine and Activity-Dependent Activation of Adenosine A ₁ Receptors. Journal of Neuroscience, 2011, 31, 6221-6234.	1.7	51
239	Analysis of gene expression in gemcitabine resistant cells derived from human pancreatic cancer cell. , 2011, , .		2
240	Identification of Cysteines Involved in the Effects of Methanethiosulfonate Reagents on Human Equilibrative Nucleoside Transporter 1. Molecular Pharmacology, 2011, 80, 735-746.	1.0	11
241	Metabolic Imaging Allows Early Prediction of Response to Vandetanib. Journal of Nuclear Medicine, 2011, 52, 231-240.	2.8	13
242	Netrin-1 Signaling Dampens Inflammatory Peritonitis. Journal of Immunology, 2011, 186, 549-555.	0.4	65
243	Strategies for therapy of retinal diseases using systemic drug delivery: relevance of transporters at the blood–retinal barrier. Expert Opinion on Drug Delivery, 2011, 8, 1571-1587.	2.4	56
244	Fetoplacental Vascular Endothelial Dysfunction as an Early Phenomenon in the Programming of Human Adult Diseases in Subjects Born from Gestational Diabetes Mellitus or Obesity in Pregnancy. Experimental Diabetes Research, 2011, 2011, 1-18.	3.8	51
245	Nucleobase Transport by Human Equilibrative Nucleoside Transporter 1 (hENT1). Journal of Biological Chemistry, 2011, 286, 32552-32562.	1.6	102
246	Adenosine Enhances Sweet Taste through A2B Receptors in the Taste Bud. Journal of Neuroscience, 2012, 32, 322-330.	1.7	73
247	Neuronal adenosine release, and not astrocytic ATP release, mediates feedback inhibition of excitatory activity. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6265-6270.	3.3	248
248	Cysteine Cross-linking Defines the Extracellular Gate for the Leishmania donovani Nucleoside Transporter 1.1 (LdNT1.1). Journal of Biological Chemistry, 2012, 287, 44036-44045.	1.6	11
249	The juvenile Batten disease protein, CLN3, and its role in regulating anterograde and retrograde post-Golgi trafficking. Clinical Lipidology, 2012, 7, 79-91.	0.4	74
250	Mechanism of Nucleoside Uptake in Rat Placenta and Induction of Placental CNT2 in Experimental Diabetes. Drug Metabolism and Pharmacokinetics, 2012, 27, 439-446.	1.1	20
251	Expression of equilibrative nucleoside transporter type 1 protein in elderly patients with schizophrenia. NeuroReport, 2012, 23, 224-227.	0.6	13
252	How systemic inflammation modulates adenosine metabolism and adenosine receptor expression in humans in vivo. Critical Care Medicine, 2012, 40, 2609-2616.	0.4	23
253	Physiological and Pharmacological Roles of Vascular Nucleoside Transporters. Journal of Cardiovascular Pharmacology, 2012, 59, 10-15.	0.8	31
254	Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenetics and Genomics, 2012, 22, 105-116.	0.7	33

#	Article	IF	CITATIONS
255	Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells. Haematologica, 2012, 97, 943-951.	1.7	17
256	Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. Journal of Clinical Investigation, 2012, 122, 693-710.	3.9	99
258	Review of ticagrelor in the management of acute coronary syndromes. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1315-1325.	1.5	1
259	The struggle for energy in podocytes leads to nephrotic syndrome. Cell Cycle, 2012, 11, 1504-1511.	1.3	17
260	A2 Adenosine Receptors and Vascular Pathologies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 870-878.	1.1	37
261	Equilibrative Nucleoside Transporter 3 Deficiency Perturbs Lysosome Function and Macrophage Homeostasis. Science, 2012, 335, 89-92.	6.0	112
262	Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model. Journal of Cardiovascular Pharmacology and Therapeutics, 2012, 17, 164-172.	1.0	173
263	Adenosine hypothesis of schizophrenia – Opportunities for pharmacotherapy. Neuropharmacology, 2012, 62, 1527-1543.	2.0	160
264	Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for <scp>HCV</scp> genotype 1b patients. Liver International, 2012, 32, 826-836.	1.9	33
265	PPARα and PPARÎ ³ regulate the nucleoside transporter hENT1. Biochemical and Biophysical Research Communications, 2012, 419, 405-411.	1.0	17
266	Nucleoside transporters: biological insights and therapeutic applications. Future Medicinal Chemistry, 2012, 4, 1461-1478.	1.1	32
267	Role of Human Nucleoside Transporters in the Uptake and Cytotoxicity of Azacitidine and Decitabine. Nucleosides, Nucleotides and Nucleic Acids, 2012, 31, 236-255.	0.4	51
268	A Mild Form of SLC29A3 Disorder: A Frameshift Deletion Leads to the Paradoxical Translation of an Otherwise Noncoding mRNA Splice Variant. PLoS ONE, 2012, 7, e29708.	1.1	50
269	Adenosine inhibits glutamatergic input to basal forebrain cholinergic neurons. Journal of Neurophysiology, 2012, 107, 2769-2781.	0.9	25
270	Adenosinergic System in the Mesenteric Vessels. , 0, , .		2
271	Inner Blood-Retinal Barrier Transporters: Relevance to Diabetic Retinopathy. , 2012, , .		5
272	Antihyperalgesic activity of nucleoside transport inhibitors in models of inflammatory pain in guinea pigs. Journal of Pain Research, 2012, 5, 391.	0.8	14
273	Regulation of Neutrophil Function by Adenosine. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 856-864.	1.1	206

ARTICLE IF CITATIONS Application of Membrane Permeability Evaluated in In Vitro Analyses to Estimate Blood–Retinal Barrier 274 1.6 16 Permeability. Journal of Pharmaceutical Sciences, 2012, 101, 2596-2605. Adenosine dysfunction in epilepsy. Clia, 2012, 60, 1234-1243. 2.5 169 Adenosine and Hypoxia-Inducible Factor Signaling in Intestinal Injury and Recovery. Annual Review of 276 5.6 111 Physiology, 2012, 74, 153-175. Attenuation of Phosphorylation by Deoxycytidine Kinase is Key to Acquired Gemcitabine Resistance in a Pancreatic Cancer Cell Line: Targeted Proteomic and Metabolomic Analyses in PK9 Cells. Pharmaceutical Research, 2012, 29, 2006-2016. Variability of gemcitabine accumulation and its relationship to expression of nucleoside transporters 278 2.7 5 in peripheral blood mononuclear cells. Archives of Pharmacal Research, 2012, 35, 921-927. ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochemical 279 Pharmacology, 2012, 83, 1073-1083. Residue lle89 in human plasma membrane monoamine transporter influences its organic cation 280 2.0 8 transport activity and sensitivity to inhibition by dilazep. Biochemical Pharmacology, 2012, 84, 383-390. 6â€mercaptopurine transport in human lymphocytes: Correlation with drugâ€induced cytotoxicity. 10 Journal of Digestive Diseases, 2012, 13, 82-93. Transporters that translocate nucleosides and structural similar drugs: structural requirements 282 5.0 57 for substrate recognition. Medicinal Research Reviews, 2012, 32, 428-457. Nucleoside transporters are widely expressed in ovarian carcinoma effusions. Cancer Chemotherapy 1.1 and Pharmacology, 2012, 69, 467-475. Circadian rhythms and sleepâ€"the metabolic connection. Pflugers Archiv European Journal of 284 17 1.3 Physiology, 2012, 463, 23-30. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of 1.8 its dose-schedule for cancer therapy. Clinical Epigenetics, 2013, 5, 3. Organic Anion Transporting Polypeptides Expressed in Pancreatic Cancer May Serve As Potential Diagnostic Markers and Therapeutic Targets for Early Stage Adenocarcinomas. Pharmaceutical 286 1.7 44 Research, 2013, 30, 2260-2269. Transport of nucleosides in the vcCNT facilitated by sodium gradients from molecular dynamics simulations. Molecular BioSystems, 2013, 9, 2142. The role of purinergic pathways in the pathophysiology of gut diseases: Pharmacological modulation 288 60 and potential therapeutic applications. , 2013, 139, 157-188. Brain nucleoside recycling. Metabolomics, 2013, 9, 271-279. 290 Adenosine Metabolism, Adenosine Kinase, and Evolution., 2013, , 23-54. 17 p90RSKs mediate the activation of ribosomal RNA synthesis by the hypertrophic agonist phenylephrine 291 in adult cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2013, 59, 139-147.

#	Article	IF	CITATIONS
292	Purinergic signaling gene network expression in bovine polymorphonuclear neutrophils during the peripartal period. Journal of Dairy Science, 2013, 96, 7675-7683.	1.4	17
293	Immunity, inflammation and cancer: a leading role for adenosine. Nature Reviews Cancer, 2013, 13, 842-857.	12.8	612
294	The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Molecular Aspects of Medicine, 2013, 34, 529-547.	2.7	285
295	Hypoxia and P1 receptor activation regulate the high-affinity concentrative adenosine transporter CNT2Âin differentiated neuronal PC12 cells. Biochemical Journal, 2013, 454, 437-445.	1.7	26
296	Cell biology and function of neuronal ceroid lipofuscinosis-related proteins. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1866-1881.	1.8	117
297	Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochemical Pharmacology, 2013, 86, 1531-1540.	2.0	46
298	Effect of linalool as a component of Humulus lupulus on doxorubicin-induced antitumor activity. Food and Chemical Toxicology, 2013, 53, 174-179.	1.8	35
299	Tubuloglomerular feedback and renal function in mice with targeted deletion of the type 1 equilibrative nucleoside transporter. American Journal of Physiology - Renal Physiology, 2013, 304, F382-F389.	1.3	13
300	An Egyptian family with H syndrome due toÂaÂnovel mutation in <i>SLC29A3</i> illustrating overlapping features with pigmented hypertrichotic dermatosis with insulin-dependent diabetes and Faisalabad histiocytosis. Pediatric Diabetes, 2013, 14, 466-472.	1.2	17
301	Glial adenosine kinase – A neuropathological marker of the epileptic brain. Neurochemistry International, 2013, 63, 688-695.	1.9	60
302	Role of equilibrative adenosine transporters and adenosine receptors as modulators of the human placental endothelium in gestational diabetes mellitus. Placenta, 2013, 34, 1121-1127.	0.7	21
303	Human equilibrative nucleoside transporter 1 (hENT1): Do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients?. Pancreatology, 2013, 13, 558-563.	0.5	13
304	Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055. Phytomedicine, 2013, 20, 1306-1314.	2.3	13
305	Loss of equilibrative nucleoside transporter 1 in mice leads to progressive ectopic mineralization of spinal tissues resembling diffuse idiopathic skeletal hyperostosis in humans. Journal of Bone and Mineral Research, 2013, 28, 1135-1149.	3.1	80
307	Measurement of Purine Release with Microelectrode Biosensors. Neuromethods, 2013, , 221-240.	0.2	1
308	Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy. Cancer Chemotherapy and Pharmacology, 2013, 71, 817-823.	1.1	29
309	Adenosine Signaling in Striatal Circuits and Alcohol Use Disorders. Molecules and Cells, 2013, 36, 195-202.	1.0	49
310	Adenosine and Autocrine Metabolic Regulation of Neuronal Activity. , 2013, , 71-85.		3

#	Article	IF	CITATIONS
311	The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 669-682.	1.1	60
312	Effect of Salt Intake on Bioavailability of Mizoribine in Healthy Japanese Males. Drug Metabolism and Pharmacokinetics, 2013, 28, 75-80.	1.1	7
313	Extracellular guanosine regulates extracellular adenosine levels. American Journal of Physiology - Cell Physiology, 2013, 304, C406-C421.	2.1	42
314	Protective effects of pentoxifylline in pulmonary inflammation are adenosine receptor A _{2A} dependent. FASEB Journal, 2013, 27, 3524-3535.	0.2	36
315	Adenosine Kinase: Exploitation for Therapeutic Gain. Pharmacological Reviews, 2013, 65, 906-943.	7.1	246
316	Long-term in vivo monitoring of mouse and human hematopoietic stem cell engraftment with a human positron emission tomography reporter gene. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1857-1862.	3.3	50
317	Basolateral Uptake of Nucleosides by Sertoli Cells Is Mediated Primarily by Equilibrative Nucleoside Transporter 1. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 121-129.	1.3	27
318	Human Concentrative Nucleoside Transporter 3 Transfection with Ultrasound and Microbubbles in Nucleoside Transport Deficient HEK293 Cells Greatly Increases Gemcitabine Uptake. PLoS ONE, 2013, 8, e56423.	1.1	25
319	Homeostatic control of brain function – new approaches to understand epileptogenesis. Frontiers in Cellular Neuroscience, 2013, 7, 109.	1.8	40
320	Na ⁺ -Independent Nucleoside Transporters Regulate Adenosine and Hypoxanthine Levels in Müller Cells and the Inner Blood–Retinal Barrier. , 2013, 54, 1469.		15
321	The Adenosine–Insulin Signaling Axis in the Fetoplacental Endothelial Dysfunction in Gestational Diabetes. , 2013, , .		2
322	Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters. ELife, 2014, 3, e03604.	2.8	50
323	Membrane transporters in a human genome-scale metabolic knowledgebase and their implications for disease. Frontiers in Physiology, 2014, 5, 91.	1.3	76
325	FUN26 (Function Unknown Now 26) Protein from Saccharomyces cerevisiae Is a Broad Selectivity, High Affinity, Nucleoside and Nucleobase Transporter. Journal of Biological Chemistry, 2014, 289, 24440-24451.	1.6	12
326	Role of soluteÂcarrier transporters in pancreatic cancer: a review. Pharmacogenomics, 2014, 15, 1133-1145.	0.6	24
327	How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Frontiers in Pharmacology, 2014, 5, 231.	1.6	136
328	Nucleobase and nucleoside transport and integration into plant metabolism. Frontiers in Plant Science, 2014, 5, 443.	1.7	72
329	Adenosine as a regulator of <scp>NF</scp> <i>κ</i> <scp>B</scp> activation. Acta Physiologica, 2014, 210, 465-467.	1.8	0

#	Article	IF	CITATIONS
330	High Risk of Embryo-Fetal Toxicity: Placental Transfer of T-2 Toxin and Its Major Metabolite HT-2 Toxin in BeWo Cells. Toxicological Sciences, 2014, 137, 168-178.	1.4	26
331	Identification of the Intracellular Gate for a Member of the Equilibrative Nucleoside Transporter (ENT) Family. Journal of Biological Chemistry, 2014, 289, 8799-8809.	1.6	29
332	Drug transporters in the nasal epithelium: an overview of strategies in targeted drug delivery. Future Medicinal Chemistry, 2014, 6, 1381-1397.	1.1	17
333	Cytidine Deaminase in Myeloprotective Gene Therapy. , 2014, , 423-440.		0
334	Organic and inorganic transporters of the testis: A review. Spermatogenesis, 2014, 4, e979653.	0.8	12
335	The Role of Nucleotides and Purinergic Signaling in Apoptotic Cell Clearance ââ,¬â€œ Implications for Chronic Inflammatory Diseases. Frontiers in Immunology, 2014, 5, 656.	2.2	36
336	Role of Insulin and Adenosine in the Human Placenta Microvascular and Macrovascular Endothelial Cell Dysfunction in Gestational Diabetes Mellitus. Microcirculation, 2014, 21, 26-37.	1.0	38
337	Syzygium cumini is more effective in preventing the increase of erythrocytic ADA activity than phenolic compounds under hyperglycemic conditions in vitro. Journal of Physiology and Biochemistry, 2014, 70, 321-30.	1.3	11
338	Chemometrics approach for the prediction of structure–activity relationship for membrane transporter bilitranslocase. SAR and QSAR in Environmental Research, 2014, 25, 853-872.	1.0	3
339	Adenosine uptake is the major effector of extracellular ATP toxicity in human cervical cancer cells. Molecular Biology of the Cell, 2014, 25, 2905-2918.	0.9	49
340	Adenosine increases LPS-induced nuclear factor kappa B activation in smooth muscle cells via an intracellular mechanism and modulates it via actions on adenosine receptors. Acta Physiologica, 2014, 210, 590-599.	1.8	9
341	The purinergic neurotransmitter revisited: A single substance or multiple players?. , 2014, 144, 162-191.		64
343	FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy. World Journal of Gastroenterology, 2014, 20, 10316.	1.4	61
346	Improvements of Doxorubicin-Induced Antitumor Activity and Adverse Reaction by Combined Citrulline. Biological and Pharmaceutical Bulletin, 2014, 37, 447-453.	0.6	2
347	Functional identification of SLC43A3 as an equilibrative nucleobase transporter involved in purine salvage in mammals. Scientific Reports, 2015, 5, 15057.	1.6	47
348	Decreased erythrocyte nucleoside transport and hENT1 transporter expression in glucose 6-phosphate dehydrogenase deficiency. BMC Hematology, 2015, 15, 17.	2.6	4
349	Equilibrative Nucleoside Transporters 1 and 4. Journal of Cardiovascular Pharmacology, 2015, 65, 517-521.	0.8	11
350	Metabolic Regulation of Uridine in the Brain. Current Metabolomics, 2015, 3, 4-9.	0.5	5

ARTICLE IF CITATIONS Identification of a Novel Mutation in Solute Carrier Family 29, Member 3 in a Chinese Patient with H 351 0.9 2 Syndrome. Chinese Medical Journal, 2015, 128, 1336-1339. The Role of Flexible Loops in Folding, Trafficking and Activity of Equilibrative Nucleoside 1.1 Transporters. PLoS ONE, 2015, 10, e0136779. ENT1 Inhibition Attenuates Epileptic Seizure Severity Via Regulation of Glutamatergic 353 1.8 17 Neurotransmission. NeuroMolecular Medicine, 2015, 17, 1-11. Identification of 8-Aminoadenosine Derivatives as a New Class of Human Concentrative Nucleoside 354 1.3 Transporter 2 Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 244-248. The nucleobase adenine as a signalling molecule in the kidney. Acta Physiologica, 2015, 213, 808-818. 355 19 1.8 Contribution of CNT1 and ENT1 to ribavirin uptake in human hepatocytes. Archives of Pharmacal 2.7 Research, 2015, 38, 904-913. Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors. Clinical 357 0.0 0 Investigation, 2015, 5, 39-46. Adenosine A1 receptor activation modulates human equilibrative nucleoside transporter 1 (hENT1) 1.7 20 activity via PKC-mediated phosphorylation of serine-281. Cellular Signalling, 2015, 27, 1008-1018. Comparative genomic and expression analysis of the adenosine signaling pathway members in Xenopus. 359 1.1 5 Purinergic Signalling, 2015, 11, 59-77. Adenosine Transporters and Receptors. Vitamins and Hormones, 2015, 98, 487-523. Equilibrative nucleoside transporter 3 depletion in Î²-cells impairs mitochondrial function and promotes apoptosis: Relationship to pigmented hypertrichotic dermatosis with insulin-dependent 361 1.8 15 diabetes. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2086-2095. An adenosine kinase inhibitor, ABT-702, inhibits spinal nociceptive transmission by adenosine release via equilibrative nucleoside transporters in rat. Neuropharmacology, 2015, 97, 160-170. Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. Frontiers in 363 1.6 84 Pharmacology, 2015, 6, 13. Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosis. Vascular Pharmacology, 2015, 71, 201-207. 364 1.0 29 Fluorescent Nucleoside Derivatives as a Tool for the Detection of Concentrative Nucleoside Transporter Activity Using Confocal Microscopy and Flow Cytometry. Molecular Pharmaceutics, 2015, 365 2.38 12, 2158-2166. Differential nucleobase protection against 5-fluorouracil toxicity for squamous and columnar cells: 1.2 implication for tissue function and oncogenesis. Investigational New Drugs, 2015, 33, 1003-1011. Thermodynamics and kinetics of inhibitor binding to human equilibrative nucleoside transporter 367 2.0 11 subtype-1. Biochemical Pharmacology, 2015, 98, 681-689. Adenosine A2A Receptors: Localization and Function. Current Topics in Neurotoxicity, 2015, , 1-25.

#	Article	IF	CITATIONS
369	Disrupted sleep–wake regulation in type 1 equilibrative nucleoside transporter knockout mice. Neuroscience, 2015, 303, 211-219.	1.1	26
370	Expression, purification and functional characterization of human equilibrative nucleoside transporter subtype-1 (hENT1) protein from Sf9 insect cells. Protein Expression and Purification, 2015, 114, 99-107.	0.6	22
371	Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment. Molecular Pharmaceutics, 2015, 12, 3282-3291.	2.3	38
372	The NLRP3 inflammasome is activated by nanoparticles through ATP, ADP and adenosine. Cell Death and Disease, 2015, 6, e1629-e1629.	2.7	162
373	Effect of Hypoxanthine on Functional Activity of Nucleoside Transporters ENT1 and ENT2 in Caco-2 Polar Epithelial Intestinal Cells. Bulletin of Experimental Biology and Medicine, 2015, 160, 160-164.	0.3	9
374	Purine import into malaria parasites as a target for antimalarial drug development. Annals of the New York Academy of Sciences, 2015, 1342, 19-28.	1.8	24
375	Novel homozygous <i>SLC29A3</i> mutations among two unrelated Egyptian families with spectral features of H-syndrome. Pediatric Diabetes, 2015, 16, 305-316.	1.2	11
376	Inhibition of Adenosine Kinase Attenuates Acute Lung Injury*. Critical Care Medicine, 2016, 44, e181-e189.	0.4	17
377	Disruption of biomineralization pathways in spinal tissues of a mouse model of diffuse idiopathic skeletal hyperostosis. Bone, 2016, 90, 37-49.	1.4	16
378	Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapyâ€naÃ⁻ve pT2 gallbladder adenocarcinoma patients. Histopathology, 2016, 68, 722-728.	1.6	15
379	Extracellular purines' action on glomerular albumin permeability in isolated rat glomeruli: insights into the pathogenesis of albuminuria. American Journal of Physiology - Renal Physiology, 2016, 311, F103-F111.	1.3	18
380	TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. Carcinogenesis, 2016, 37, 1041-1051.	1.3	67
381	The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition. Clinical Pharmacology and Therapeutics, 2016, 100, 489-499.	2.3	54
382	Effect of dipyridamole on myocardial reperfusion injury: A doubleâ€blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery. Clinical Pharmacology and Therapeutics, 2016, 99, 381-389.	2.3	4
383	Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. Pharmacological Research, 2016, 111, 501-508.	3.1	19
384	The SLC28 (CNT) and SLC29 (ENT) nucleoside transporter families: a 30-year collaborative odyssey. Biochemical Society Transactions, 2016, 44, 869-876.	1.6	83
385	Compound heterozygous SLC29A3 mutation causes H syndrome in a Moroccan patient: A case report. Current Research in Translational Medicine, 2016, 64, 65-68.	1.2	8
386	Substrate and Inhibitor Specificity of the <i>Plasmodium berghei</i> Equilibrative Nucleoside Transporter Type 1. Molecular Pharmacology, 2016, 89, 678-685.	1.0	8

#	Article	IF	CITATIONS
387	The role of the equilibrative nucleoside transporter 1 on tissue and fetal distribution of ribavirin in the mouse. Biopharmaceutics and Drug Disposition, 2016, 37, 336-344.	1.1	10
388	Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development. International Journal for Parasitology: Drugs and Drug Resistance, 2016, 6, 1-11.	1.4	16
389	Identification of Adenine and Benzimidazole Nucleosides as Potent Human Concentrative Nucleoside Transporter 2 Inhibitors: Potential Treatment for Hyperuricemia and Gout. Journal of Medicinal Chemistry, 2016, 59, 3719-3731.	2.9	16
390	A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. Molecular Pharmacology, 2016, 89, 263-272.	1.0	21
391	Proteogenomic Analysis of a Hibernating Mammal Indicates Contribution of Skeletal Muscle Physiology to the Hibernation Phenotype. Journal of Proteome Research, 2016, 15, 1253-1261.	1.8	33
392	Drug Transport Across Blood-Ocular Barriers and Pharmacokinetics. , 2016, , 37-63.		5
393	Purinergic regulation of the immune system. Nature Reviews Immunology, 2016, 16, 177-192.	10.6	607
394	Nucleoside recycling in the brain and the nucleosidome: a complex metabolic and molecular cross-talk between the extracellular nucleotide cascade system and the intracellular nucleoside salvage. Metabolomics, 2016, 12, 1.	1.4	9
395	Visualizing nucleic acid metabolism using non-natural nucleosides and nucleotide analogs. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2016, 1864, 165-176.	1.1	8
396	Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia. Blood Reviews, 2016, 30, 55-64.	2.8	39
397	Adenosine contribution to normal renal physiology and chronic kidney disease. Molecular Aspects of Medicine, 2017, 55, 75-89.	2.7	34
398	A semi-quantitative translational pharmacology analysis to understand the relationship between in vitro ENT1 inhibition and the clinical incidence of dyspnoea and bronchospasm. Toxicology and Applied Pharmacology, 2017, 317, 41-50.	1.3	10
399	Adenosine receptors: Modulators of lipid availability that are controlled by lipid levels. Molecular Aspects of Medicine, 2017, 55, 26-44.	2.7	31
400	Engineering Therapeutic Enzymes. , 2017, , 17-67.		4
401	Erythrocytes retain hypoxic adenosine response for faster acclimatization upon re-ascent. Nature Communications, 2017, 8, 14108.	5.8	81
402	Functional reconstitution of human equilibrative nucleoside transporter-1 into styrene maleic acid co-polymer lipid particles. Biochimica Et Biophysica Acta - Biomembranes, 2017, 1859, 1059-1065.	1.4	29
403	Functional characterization of human equilibrative nucleoside transporter 1. Protein and Cell, 2017, 8, 284-295.	4.8	27
404	Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells. Drug Metabolism and Pharmacokinetics, 2017, 32, 301-310.	1.1	5

#	Article	IF	Citations
405	Molecular determinants of acidic pH-dependent transport of human equilibrative nucleoside transporter 3. Journal of Biological Chemistry, 2017, 292, 14775-14785.	1.6	22
406	Toward a structural understanding of nucleic acidâ€sensing Tollâ€like receptors in the innate immune system. FEBS Letters, 2017, 591, 3167-3181.	1.3	29
407	Blood purine measurements as a rapid real-time indicator of reversible brain ischaemia. Purinergic Signalling, 2017, 13, 521-528.	1.1	25
408	The Novel Membrane-Bound Proteins MFSD1 and MFSD3 are Putative SLC Transporters Affected by Altered Nutrient Intake. Journal of Molecular Neuroscience, 2017, 61, 199-214.	1.1	39
409	Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. Nature Reviews Rheumatology, 2017, 13, 41-51.	3.5	189
410	Multiple pathways for elevating extracellular adenosine in the rat hippocampal <scp>CA</scp> 1 region characterized by adenosine sensor cells. Journal of Neurochemistry, 2017, 140, 24-36.	2.1	11
411	Equilibrative nucleoside transporters—A review. Nucleosides, Nucleotides and Nucleic Acids, 2017, 36, 7-30.	0.4	146
412	Insulin/adenosine axis linked signalling. Molecular Aspects of Medicine, 2017, 55, 45-61.	2.7	50
413	Molecular Basis of Nucleobase Transport Systems in Mammals. Biological and Pharmaceutical Bulletin, 2017, 40, 1130-1138.	0.6	25
414	Adenosine A1 and A2A Receptors in the Brain: Current Research and Their Role in Neurodegeneration. Molecules, 2017, 22, 676.	1.7	140
415	Anti-inflammatory Effects of Heme Oxygenase-1 Depend on Adenosine A2A- and A2B-Receptor Signaling in Acute Pulmonary Inflammation. Frontiers in Immunology, 2017, 8, 1874.	2.2	21
416	Brain and the Drug Transporters. , 2017, , 35-67.		1
417	The Adenosinergic System as a Therapeutic Target in the Vasculature: New Ligands and Challenges. Molecules, 2017, 22, 752.	1.7	23
418	Genome Editing in Neuroepithelial Stem Cells to Generate Human Neurons with High Adenosine-Releasing Capacity. Stem Cells Translational Medicine, 2018, 7, 477-486.	1.6	8
419	Identification of Structural and Molecular Features Involved in the Transport of 3′-Deoxy-Nucleoside Analogs by Human Equilibrative Nucleoside Transporter 3. Drug Metabolism and Disposition, 2018, 46, 600-609.	1.7	5
420	Adenosine metabolism, immunity and joint health. Biochemical Pharmacology, 2018, 151, 307-313.	2.0	54
421	Glycodendrimer Nanocarriers for Direct Delivery of Fludarabine Triphosphate to Leukemic Cells: Improved Pharmacokinetics and Pharmacodynamics of Fludarabine. Biomacromolecules, 2018, 19, 531-543.	2.6	30
422	Efflux proteins at the blood–brain barrier: review and bioinformatics analysis. Xenobiotica, 2018, 48, 506-532.	0.5	28

#	Article	IF	CITATIONS
423	Enhancement of inosine-mediated A 2A R signaling through positive allosteric modulation. Cellular Signalling, 2018, 42, 227-235.	1.7	34
424	Vascular Sympathetic Neurotransmission and Endothelial Dysfunction. , 0, , .		1
425	mRNA Expression and Activity of Nucleoside Transporters in Human Hepatoma HepaRG Cells. Pharmaceutics, 2018, 10, 246.	2.0	7
426	Molecular Characterization of Equilibrative Nucleoside Transporters in the Rat Carotid Body and Their Regulation by Chronic Hypoxia. Advances in Experimental Medicine and Biology, 2018, 1071, 43-50.	0.8	4
427	Adenosine Actions on Oligodendroglia and Myelination in Autism Spectrum Disorder. Frontiers in Cellular Neuroscience, 2018, 12, 482.	1.8	21
428	H syndrome: Clinical, histological and genetic investigation in Tunisian patients. Journal of Dermatology, 2018, 45, 978-985.	0.6	13
429	Expression of Concentrative Nucleoside Transporters (<i>SLC28A</i>) in the Human Placenta: Effects of Gestation Age and Prototype Differentiation-Affecting Agents. Molecular Pharmaceutics, 2018, 15, 2732-2741.	2.3	15
430	Regulation of hepatic glucose production and AMPK by AICAR but not by metformin depends on drug uptake through the equilibrative nucleoside transporter 1 (ENT1). Diabetes, Obesity and Metabolism, 2018, 20, 2748-2758.	2.2	10
431	Purinergic modulation of glutamate transmission: An expanding role in stress-linked neuropathology. Neuroscience and Biobehavioral Reviews, 2018, 93, 26-37.	2.9	9
432	Regulation of Extracellular Adenosine. , 2018, , 13-32.		6
432 433	Regulation of Extracellular Adenosine. , 2018, , 13-32. Emerging Roles of Nucleoside Transporters. Frontiers in Pharmacology, 2018, 9, 606.	1.6	6 105
		1.6	
433	Emerging Roles of Nucleoside Transporters. Frontiers in Pharmacology, 2018, 9, 606. Deoxyribonucleotide Triphosphate Metabolism in Cancer and Metabolic Disease. Frontiers in		105
433 434	Emerging Roles of Nucleoside Transporters. Frontiers in Pharmacology, 2018, 9, 606. Deoxyribonucleotide Triphosphate Metabolism in Cancer and Metabolic Disease. Frontiers in Endocrinology, 2018, 9, 177.	1.5	105 58
433 434 435	Emerging Roles of Nucleoside Transporters. Frontiers in Pharmacology, 2018, 9, 606. Deoxyribonucleotide Triphosphate Metabolism in Cancer and Metabolic Disease. Frontiers in Endocrinology, 2018, 9, 177. The Inside Story of Adenosine. International Journal of Molecular Sciences, 2018, 19, 784. A conserved major facilitator superfamily member orchestrates a subset of O-glycosylation to aid	1.5 1.8	105 58 52
433 434 435 436	Emerging Roles of Nucleoside Transporters. Frontiers in Pharmacology, 2018, 9, 606. Deoxyribonucleotide Triphosphate Metabolism in Cancer and Metabolic Disease. Frontiers in Endocrinology, 2018, 9, 177. The Inside Story of Adenosine. International Journal of Molecular Sciences, 2018, 19, 784. A conserved major facilitator superfamily member orchestrates a subset of O-glycosylation to aid macrophage tissue invasion. ELife, 2019, 8, . A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells. Cancer Chemotherapy	1.5 1.8 2.8	105 58 52 24
433 434 435 436 437	Emerging Roles of Nucleoside Transporters. Frontiers in Pharmacology, 2018, 9, 606. Deoxyribonucleotide Triphosphate Metabolism in Cancer and Metabolic Disease. Frontiers in Endocrinology, 2018, 9, 177. The Inside Story of Adenosine. International Journal of Molecular Sciences, 2018, 19, 784. A conserved major facilitator superfamily member orchestrates a subset of O-glycosylation to aid macrophage tissue invasion. ELife, 2019, 8,. A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells. Cancer Chemotherapy and Pharmacology, 2019, 84, 739-748.	1.5 1.8 2.8 1.1	105 58 52 24 2

#	Article	IF	CITATIONS
441	Current Progress on Equilibrative Nucleoside Transporter Function and Inhibitor Design. SLAS Discovery, 2019, 24, 953-968.	1.4	15
442	Label-free detection of transporter activity via GPCR signalling in living cells: A case for SLC29A1, the equilibrative nucleoside transporter 1. Scientific Reports, 2019, 9, 13802.	1.6	16
443	Squalene-Adenosine Nanoparticles: Ligands of Adenosine Receptors or Adenosine Prodrug?. Journal of Pharmacology and Experimental Therapeutics, 2019, 369, 144-151.	1.3	15
444	Fludarabine-Specific Molecular Interactions with Maltose-Modified Poly(propyleneimine) Dendrimer Enable Effective Cell Entry of the Active Drug Form: Comparison with Clofarabine. Biomacromolecules, 2019, 20, 1429-1442.	2.6	16
445	A novel 3′ untranslated region mutation in the <i>SLC29A3</i> gene associated with pigmentary hypertrichosis and nonâ€autoimmune insulinâ€dependent diabetes mellitus syndrome. Pediatric Diabetes, 2019, 20, 474-481.	1.2	4
446	Accessibility of substituted cysteines in TM2 and TM10 transmembrane segments in the Plasmodium falciparum equilibrative nucleoside transporter PfENT1. Journal of Biological Chemistry, 2019, 294, 1924-1935.	1.6	3
447	Purinergic signaling in the retina: From development to disease. Brain Research Bulletin, 2019, 151, 92-108.	1.4	25
448	Loss of ENT1 increases cell proliferation in the annulus fibrosus of the intervertebral disc. Journal of Cellular Physiology, 2019, 234, 13705-13719.	2.0	9
449	Vascular impairment of adenosinergic system in hypertension: increased adenosine bioavailability and differential distribution of adenosine receptors and nucleoside transporters. Histochemistry and Cell Biology, 2019, 151, 407-418.	0.8	3
450	Oligomerization of equilibrative nucleoside transporters: a novel regulatory and functional mechanism involving PKC and PP1. FASEB Journal, 2019, 33, 3841-3850.	0.2	10
451	Role of insulin, adenosine, and adipokine receptors in the foetoplacental vascular dysfunction in gestational diabetes mellitus. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165370.	1.8	17
452	Interplay Between Cholinergic and Adenosinergic Systems in Skeletal Muscle. Neuroscience, 2020, 439, 41-47.	1.1	2
453	Blockade of equilibrative nucleoside transporter 1/2 protects against <i>Pseudomonas aeruginosa–</i> induced acute lung injury and NLRP3 inflammasome activation. FASEB Journal, 2020, 34, 1516-1531.	0.2	19
454	Functional Analysis of the Role of Equilibrative Nucleobase Transporter 1 (ENBT1/SLC43A3) in Adenine Transport in HepG2ÂCells. Journal of Pharmaceutical Sciences, 2020, 109, 2622-2628.	1.6	4
455	Preparation of 5-[1311]iodotubercidin for the detection of adenosine kinase. Journal of Radioanalytical and Nuclear Chemistry, 2020, 326, 1691-1697.	0.7	0
456	Equilibrative Nucleoside Transporter 2: Properties and Physiological Roles. BioMed Research International, 2020, 2020, 1-8.	0.9	16
457	Nucleoside Reverse Transcriptase Inhibitor Interaction with Human Equilibrative Nucleoside Transporters 1 and 2. Drug Metabolism and Disposition, 2020, 48, 603-612.	1.7	15
458	Nucleoside transporters are critical to the uptake and antioxidant activity of 7,8-dihydroneopterin in monocytic cells. Free Radical Research, 2020, 54, 341-350.	1.5	6

ARTICLE IF CITATIONS # Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update. Cellular Oncology 459 2.1 44 (Dordrecht), 2020, 43, 989-1001. Purines: From Diagnostic Biomarkers to Therapeutic Agents in Brain Injury. Neuroscience Bulletin, 1.5 2020, 36, 1315-1326. Expansion of the Major Facilitator Superfamily (MFS) to include novel transporters as well as 461 1.4 40 transmembrane-acting enzymes. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183277. H syndrome with a possibly new immunological phenotype. International Journal of Dermatology, 0.5 2020, 59, e248-e251. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma. Biochimie, 2020, 463 1.3 18 176, 21-30. SAMHD1â€deficient fibroblasts from Aicardiâ€GoutiÃ[™]res Syndrome patients can escape senescence and 464 0.2 accumulate mutations. FASEB Journal, 2020, 34, 631-647 Toward a Molecular Basis of Cellular Nucleoside Transport in Humans. Chemical Reviews, 2021, 121, 465 23.0 19 5336-5358. Adenosine Signaling in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1270, 145-167. 0.8 466 Adaptative mechanism of the equilibrative nucleoside transporter 1 (ENT-1) and blood adenosine levels 467 1.2 2 in elite freedivers. European Journal of Applied Physiology, 2021, 121, 279-285. The Structure and Mechanism of Drug Transporters. Methods in Molecular Biology, 2021, 2342, 193-234. 0.4 SLC46A1 Haplotype with Predicted Functional Impact has Prognostic Value in Breast Carcinoma. 469 2 1.6 Molecular Diagnosis and Therapy, 2021, 25, 99-110. Brain Plasma Membrane Monoamine Transporter in Health and Disease. Handbook of Experimental 0.9 Pharmacology, 2021, 266, 253-280. Hyperhomocysteinemia and Cardiovascular Disease: Is the Adenosinergic System the Missing Link?. 471 1.8 42 International Journal of Molecular Sciences, 2021, 22, 1690. Robust and flexible platform for directed evolution of yeast genetic switches. Nature 5.8 Communications, 2021, 12, 1846. Hepatic transporterâ€mediated pharmacokinetic drug–drug interactions: Recent studies and regulatory 473 1.1 3 recommendations. Biopharmaceutics and Drug Disposition, 2021, 42, 45-77. Seasonal changes in adenosine kinase in tanycytes of the Arctic ground squirrel (Urocitellus parryii). 474 Journal of Chemical Neuroanatomy, 2021, 113, 101920. Multiple Computational Approaches for Predicting Drug Interactions with Human Equilibrative 475 1.7 9 Nucleoside Transporter 1. Drug Metabolism and Disposition, 2021, 49, 479-489. 476 Metabolic Aspects of Adenosine Functions in the Brain. Frontiers in Pharmacology, 2021, 12, 672182. 1.6

#	Article	IF	CITATIONS
477	Surface AMP deaminase 2 as a novel regulator modifying extracellular adenine nucleotide metabolism. FASEB Journal, 2021, 35, e21684.	0.2	3
478	Differential Inhibition of Equilibrative Nucleoside Transporter 1 (ENT1) Activity by Tyrosine Kinase Inhibitors. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 625-635.	0.6	3
479	First we eat, then we do everything else: The dynamic metabolic regulation of efferocytosis. Cell Metabolism, 2021, 33, 2126-2141.	7.2	30
480	Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine. Clinical Pharmacokinetics, 2021, 60, 1509-1535.	1.6	7
481	Anti-Inflammatory Effects of Endogenously Released Adenosine in Synovial Cells of Osteoarthritis and Rheumatoid Arthritis Patients. International Journal of Molecular Sciences, 2021, 22, 8956.	1.8	10
482	Model Analysis of the Apparent Saturation Kinetics of Purine Nucleobase Uptake in Cells co-Expressing Transporter and Metabolic Enzyme. Pharmaceutical Research, 2021, 38, 1585-1592.	1.7	1
483	ATP and adenosine—Two players in the control of seizures and epilepsy development. Progress in Neurobiology, 2021, 204, 102105.	2.8	47
484	Transport Characteristics of 6-Mercaptopurine in Brain Microvascular Endothelial Cells Derived From Human Induced Pluripotent Stem Cells. Journal of Pharmaceutical Sciences, 2021, 110, 3484-3490.	1.6	4
485	Ectopic mineralisation of the mandibular symphysis in ENT1 knockout mice: A model of dystrophic calcification. Bone Reports, 2021, 15, 101100.	0.2	1
487	Choline and Its Products Acetylcholine and Phosphatidylcholine. , 2009, , 443-501.		15
488	Opposite Modulation of Peripheral Inflammation and Neuroinflammation by Adenosine A2A Receptors. , 2007, , 53-79.		6
489	Mechanisms of transmitter release from astrocytes. , 2009, , 301-350.		10
490	The Inner Blood-Retinal Barrier. Advances in Experimental Medicine and Biology, 2013, , 85-104.	0.8	55
491	Molecular Mechanisms of the Inner Blood-Retinal Barrier Transporters. , 2008, , 139-154.		1
492	Possible Incorporation of Free N7-Platinated Guanines in DNA by DNA Polymerases, Relevance for the Cisplatin Mechanism of Action. , 2009, , 125-132.		5
493	Essential Role of Mitochondria in Pyrimidine Metabolism. , 2015, , 287-311.		6
494	Mechanisms Regulating Airway Nucleotides. Sub-Cellular Biochemistry, 2011, 55, 17-49.	1.0	10
495	Roles of Drug Transporters in Blood-Retinal Barrier. Advances in Experimental Medicine and Biology, 2019, 1141, 467-504.	0.8	31

#	Article	IF	Citations
496	ENT1 inhibition attenuates apoptosis by activation of cAMP/pCREB/Bcl2 pathway after MCAO in rats. Experimental Neurology, 2020, 331, 113362.	2.0	23
497	Gene expression network analysis provides potential targets against SARS-CoV-2. Scientific Reports, 2020, 10, 21863.	1.6	9
498	Genetic variations in microRNA-binding sites of solute carrier transporter genes as predictors of clinical outcome in colorectal cancer. Carcinogenesis, 2021, 42, 378-394.	1.3	6
500	Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis. Journal of Clinical Investigation, 2013, 123, 3552-3563.	3.9	206
501	The Molecular Basis of Xenobiotic Transport and Metabolism in Choroid Plexus. , 2005, , 147-173.		1
502	Current Understanding of the Intestinal Absorption of Nucleobases and Analogs. Biological and Pharmaceutical Bulletin, 2020, 43, 1293-1300.	0.6	4
503	Fluorescent In Situ Folding Control for Rapid Optimization of Cell-Free Membrane Protein Synthesis. PLoS ONE, 2012, 7, e42186.	1.1	21
504	Relaxation Effect of Abacavir on Rat Basilar Arteries. PLoS ONE, 2015, 10, e0123043.	1.1	4
505	Organic cation transporter 1 (OCT1) is involved in pentamidine transport at the human and mouse blood-brain barrier (BBB). PLoS ONE, 2017, 12, e0173474.	1.1	31
506	Combination treatment with 6-mercaptopurine and allopurinol in HepG2 and HEK293 cells – Effects on gene expression levels and thiopurine metabolism. PLoS ONE, 2017, 12, e0173825.	1.1	6
507	Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters Acta Biochimica Polonica, 2005, 52, 749-758.	0.3	90
508	Enzymology of Pyrimidine Metabolism and Neurodegeneration. Current Medicinal Chemistry, 2016, 23, 1408-1431.	1.2	27
509	Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?. Current Pharmaceutical Design, 2014, 20, 1422-1449.	0.9	201
510	Strategies for Skeletal Muscle Targeting in Drug Discovery. Current Pharmaceutical Design, 2015, 21, 1327-1336.	0.9	19
511	Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression. Current Pharmaceutical Design, 2016, 22, 1049-1059.	0.9	15
512	Nucleoside Transporter Proteins. Current Vascular Pharmacology, 2009, 7, 426-434.	0.8	135
513	Do Adenosine Receptors Offer New Therapeutic Options for Diabetic Nephropathy?. Current Vascular Pharmacology, 2009, 7, 450-459.	0.8	8
514	Vascular Adenosine Receptors; Potential Clinical Applications. Current Vascular Pharmacology, 2013, 11, 327-337.	0.8	13

		CITATION REPO	ORT	
# 515	ARTICLE Functional Link Between Adenosine and Insulin: A Hypothesis for Fetoplacental Vascular Endothelia Dysfunction in Gestational Diabetes. Current Vascular Pharmacology, 2011, 9, 750-762.	al	IF 0.8	Citations 21
516	An Essential Role for Adenosine Signaling in Alcohol Abuse. Current Drug Abuse Reviews, 2010, 3, 163-174.		3.4	58
517	Adenosine: An immune modulator of inflammatory bowel diseases. World Journal of Gastroenterology, 2009, 15, 4491.		1.4	57
518	Mechanisms Responsible for Different Rates of Uptake of Mizoribine and Ribavirin by Human Epith LS 180 Cells. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2010, 900-905.		0.0	3
519	Sodium Dependent, Concentrative Nucleoside Transporters. , 2007, , 1-5.			0
520	ENT1, Equilibrative Nucleoside Transporter 1. , 2007, , 1-7.			1
521	Facilitated, Equilibrative Nucleoside Transporters. , 2007, , 1-7.			0
522	Lysosomal Membrane Transport in the Central Nervous System. , 2007, , 439-459.			0
523	ENT2, Equilibrative Nucleoside Transporter 2. , 2007, , 1-5.			0
525	Systemic Route for Retinal Drug Delivery: Role of the Blood-Retinal Barrier. AAPS Advances in the Pharmaceutical Sciences Series, 2011, , 85-109.		0.2	1
526	Targeting Adenosine Receptors for the Treatment of Melanoma. , 0, , .			0
527	Transport Mechanisms of Nucleosides and Nucleoside Analogues ReverseTranscriptase Inhibitors in the Brain. , 0, , .	1		0
528	Gene Expression Analysis In Gemcitabine Resistant Cells Derived From Human Pancreatic Cancer C Journal of Convergence Information Technology, 2011, 6, 460-466.	ell.	0.1	1
529	Molecular Biology of Mantle Cell Lymphoma. , 2012, , 113-135.			0
530	Adenosinergic Perspectives on Schizophrenia: Opportunity for an Integrative Synthesis. , 2013, , 4	59-491.		0
531	Disruption of Adenosine Homeostasis in Epilepsy and Therapeutic Adenosine Augmentation. , 2013 561-579.	В,,		0
532	Gestational Diabetes Mellitus and the Role of Adenosine in the Human Placental Endothelium and Central Nervous System. Global Journal of Pathology and Microbiology, 0, , .		0.0	1
534	Energy and Mammalian Target of Rapamycin Complex 1 (mTORC1) in Minimal Change Nephrotic Syndrome. , 2016, , 63-79.			0

ARTICLE

IF CITATIONS

535 Intestinal Absorption Mechanisms of Mizoribine without Sodium Intake. Iryo Yakugaku (Japanese) Tj ETQq0 0 0 rgBT Overlock 10 Tf 50

536	Antiretroviral Therapy: Brain Penetration. , 2017, , 405-434.		0
537	Adenosine Receptors and Drug Discovery in the Cardiovascular System. Frontiers in Cardiovascular Drug Discovery, 2019, , 65-82.	0.0	0
540	Mechanisms of Breast Cancer Resistance to Chemotherapy. , 2006, , 783-803.		0
542	How much do antiretroviral drugs penetrate into the central nervous system?. Journal of Medicine and Life, 2011, 4, 432-9.	0.4	68
543	Insights to the evolution of Nucleobase-Ascorbate Transporters (NAT/NCS2 family) from the Cys-scanning analysis of xanthine permease XanQ. International Journal of Biochemistry and Molecular Biology, 2012, 3, 250-72.	0.1	33
544	Synthesis and preclinical evaluation of a new C-6 alkylated pyrimidine derivative as a PET imaging agent for HSV1-tk gene expression. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 71-84.	1.0	3
545	Adenosine kinase is a new therapeutic target to prevent ischemic neuronal death. The Open Drug Discovery Journal, 2010, 2, 108-118.	0.8	10
549	Polyphenols-absorption and occurrence in the body system. Food Science and Technology Research, 2022, 28, 13-33.	0.3	6
550	Adenosine Blood Level: A Biomarker of White Matter Damage in Very Low Birth Weight Infants. Current Pediatric Reviews, 2022, 18, 153-163.	0.4	2
551	Augustine Blood Group System and Equilibrative Nucleoside Transporter 1. Transfusion Medicine and Hemotherapy, 2022, 49, 25-29.	0.7	3
552	Structure-Activity Relationship Studies of 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-triazin-2-amine (FPMINT) Analogues as Inhibitors of Human Equilibrative Nucleoside Transporters. Frontiers in Pharmacology, 2022, 13, 837555.	1.6	1
553	Re-Discovery of Pyrimidine Salvage as Target in Cancer Therapy. Cells, 2022, 11, 739.	1.8	19
554	Strategies for Successful Over-Expression of Human Membrane Transport Systems Using Bacterial Hosts: Future Perspectives. International Journal of Molecular Sciences, 2022, 23, 3823.	1.8	5
555	Therapeutic Potential of Highly Selective A3 Adenosine Receptor Ligands in the Central and Peripheral Nervous System. Molecules, 2022, 27, 1890.	1.7	7
556	Cerebrospinal fluid purinomics as a biomarker approach to predict outcome after severe traumatic brain injury. Journal of Neurochemistry, 2022, 161, 173-186.	2.1	5
561	Effect of Adenosine Receptor Antagonists on Adenosine-Pretreated PC12 Cells Exposed to Paraquat. Dose-Response, 2022, 20, 155932582210934.	0.7	0
564	Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomedicine and Pharmacotherapy, 2022, 150, 113074.	2.5	30

-			_		
\sim	ITAT	101	ιр	ED.	ORT
<u> </u>	IIAI	IUI	V I V	E P	UKL

#	Article	IF	CITATIONS
565	3′-Azido-2′,3′-Dideoxythymidine (Zidovudine) Uptake Mechanisms in T Lymphocytes. Antiviral Therapy, 2 11, 803-812.	006	18
566	Altered Expression of Nucleoside Transporter Genes (SLC28 and SLC29) in Adipose Tissue from HIV-1–Infected Patients. Antiviral Therapy, 2007, 12, 853-864.	0.6	21
567	Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Cancers, 2022, 14, 2486.	1.7	29
569	Mitochondrial Membranes and Mitochondrial Genome: Interactions and Clinical Syndromes. Membranes, 2022, 12, 625.	1.4	2
570	Adenosine derivatives from Cordyceps exert antitumor effects against ovarian cancer cells through ENT1-mediated transport, induction of AMPK signaling, and consequent autophagic cell death. Biomedicine and Pharmacotherapy, 2022, 153, 113491.	2.5	5
571	Novel variants provide differential stabilisation of human equilibrative nucleoside transporter 1 states. Frontiers in Molecular Biosciences, 0, 9, .	1.6	0
572	Adenosine-independent regulation of the sleep–wake cycle by astrocyte activity. Cell Discovery, 2023, 9, .	3.1	14
573	Equilibrative nucleoside transporter 3 promotes the progression of hepatocellular carcinoma by regulating the AKT/mTOR signaling pathway. International Journal of Biological Macromolecules, 2023, 241, 124323.	3.6	0
594	Endosomal Toll-Like Receptors as Therapeutic Targets for Autoimmune Diseases. Advances in Experimental Medicine and Biology, 2024, , 97-108.	0.8	0